Cardiovascular Disease Clinical Trial
Official title:
Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol
Background:
- Cardiovascular disease (CVD) is a leading cause of death in developed countries.
Although statin-type drugs are currently the most effective therapeutic agents for
reducing CVD risk. One possible complementary approach involves the use of soluble
dietary fibers that are known to reduce blood cholesterol levels. However, analysis has
shown that most soluble fibers reduce total cholesterol levels by relatively small
amounts.
- Alpha-Cyclodextrin (Alpha-CD), also sold in commerical form, is a soluble fiber derived
from corn that is used as an ingredient in many foods, such as bread rolls, crackers,
juices, and reduced fat spreads. It is added to food primarily as a fiber supplement
but is also used to stabilize flavors, colors, vitamins, and fatty acids. Studies in
animals and humans have shown that Alpha-CD may help to improve insulin resistance and
lower LDL cholesterol levels with no apparent side effects. More research is needed to
determine the effect of Alpha-CD on total cholesterol levels in healthy volunteers.
Objectives:
- To determine the effect of oral Alpha-CD on total cholesterol in a nondiabetic population.
This single center, double-blinded, cross-over, placebo controlled clinical pilot study will
investigate the effectiveness of a soluble dietary fiber, alpha-cyclodextrin (alpha-CD), on
blood lipid and lipoprotein levels in healthy human subjects. alpha-CD, a cyclical polymer
of glucose, is currently sold as an over the counter food supplement and is a common
ingredient in many foods. This is the first study that will evaluate the effect of alpha-CD
in healthy subjects. One gram of alpha-CD has been shown to bind as much as 9 grams of
dietary fat, and like other soluble dietary fibers or bile acid sequestrants (BAS) it may
decrease the intestinal absorption of fats, which has been shown to reduce the incidence of
cardiovascular disease (CVD). Animal studies in our laboratory have shown that oral alpha-CD
lowers Low Density Lipoprotein-cholesterol (LDL-C) by approximately 15 percent in mice on a
high fat diet. Other clinical trials utilizing this compound showed that it is a safe
therapy with no significant side effects.
Eligibility:
- Individuals between 18 and 75 years of age who do not have type 1 or type 2 diabetes.
Design:
- This study will require three visits to the NIH Clinical Center.
- At the first visit, participants will provide information about current diet and
exercise routines, and will have a physical examination with blood and urine tests. At
the end of this visit, participants will be randomized to receive either Alpha-CD or
placebo, and will be asked to take two 1 gram tablets three times a day, anytime from 1
hour before to the end of each meal. Participants will take a total of six tablets per
day for 12 weeks.
- At the end of the first 12 weeks, participants will return to the clinical center for
another interview and examination, and blood and urine tests. At the end of this visit,
participants will receive the treatment not given in the first part of the study
(either Alpha-CD or placebo), and will take tablets on the same schedule as before for
12 more weeks.
- Participants will wait for 1 week after stopping the previous study prescription before
starting the next one.
- At the end of the second 12 weeks, participants will have a final interview and
examination with blood and urine tests.
- Participants will be asked to keep 7-day food records before each clinic visit to be
collected at the second and third visits. A short physical activity assessment will be
collected at each visit to review any changes in physical activity.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02122198 -
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
|
N/A | |
Completed |
NCT02502812 -
Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04216342 -
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT03654313 -
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
|
Phase 1 | |
Completed |
NCT03646656 -
Heart Health Buddies: Peer Support to Decrease CVD Risk
|
N/A | |
Completed |
NCT02081066 -
Identification of CETP as a Marker of Atherosclerosis
|
N/A | |
Completed |
NCT02147626 -
Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia
|
N/A | |
Recruiting |
NCT03095261 -
Incentives in Cardiac Rehabilitation
|
N/A | |
Completed |
NCT02998918 -
Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL
|
N/A | |
Completed |
NCT02589769 -
Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons
|
N/A | |
Completed |
NCT02711878 -
Healing Hearts and Mending Minds in Older Adults Living With HIV
|
N/A | |
Not yet recruiting |
NCT02578355 -
National Plaque Registry and Database
|
N/A | |
Completed |
NCT02868710 -
Individual Variability to Aerobic Exercise Training
|
N/A | |
Recruiting |
NCT02885792 -
Coronary Artery Disease in Patients Suffering From Schizophrenia
|
N/A | |
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Completed |
NCT02640859 -
Investigation of Metabolic Risk in Korean Adults
|
||
Completed |
NCT02272946 -
Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk
|
Phase 2 | |
Completed |
NCT02657382 -
Mental Stress Ischemia: Biofeedback Study
|
N/A | |
Recruiting |
NCT02265250 -
Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment
|
||
Active, not recruiting |
NCT02600338 -
Meta-analyses of the Effect of Legumes on Blood Pressure
|
N/A |